GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Asset Turnover
中文

Amedisys (Amedisys) Asset Turnover

: 0.28 (As of Dec. 2023)
View and export this data going back to 1994. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Amedisys's Revenue for the three months ended in Dec. 2023 was $571 Mil. Amedisys's Total Assets for the quarter that ended in Dec. 2023 was $2,044 Mil. Therefore, Amedisys's Asset Turnover for the quarter that ended in Dec. 2023 was 0.28.

Asset Turnover is linked to ROE % through Du Pont Formula. Amedisys's annualized ROE % for the quarter that ended in Dec. 2023 was 7.34%. It is also linked to ROA % through Du Pont Formula. Amedisys's annualized ROA % for the quarter that ended in Dec. 2023 was 3.78%.


Amedisys Asset Turnover Historical Data

The historical data trend for Amedisys's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.98 1.46 1.29 1.16 1.11

Amedisys Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 0.28 0.28 0.28

Competitive Comparison

For the Medical Care Facilities subindustry, Amedisys's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amedisys Asset Turnover Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Amedisys's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Amedisys's Asset Turnover falls into.



Amedisys Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Amedisys's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=2236.382/( (1976.245+2060.17)/ 2 )
=2236.382/2018.2075
=1.11

Amedisys's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=570.788/( (2027.417+2060.17)/ 2 )
=570.788/2043.7935
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Amedisys  (NAS:AMED) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Amedisys's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=77.288/1053.211
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(77.288 / 2283.152)*(2283.152 / 2043.7935)*(2043.7935/ 1053.211)
=Net Margin %*Asset Turnover*Equity Multiplier
=3.39 %*1.1171*1.9405
=ROA %*Equity Multiplier
=3.78 %*1.9405
=7.34 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Amedisys's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=77.288/2043.7935
=(Net Income / Revenue)*(Revenue / Total Assets)
=(77.288 / 2283.152)*(2283.152 / 2043.7935)
=Net Margin %*Asset Turnover
=3.39 %*1.1171
=3.78 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Amedisys Asset Turnover Related Terms

Thank you for viewing the detailed overview of Amedisys's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Amedisys (Amedisys) Business Description

Traded in Other Exchanges
Address
3854 American Way, Suite A, Baton Rouge, LA, USA, 70816
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Executives
Allyson Guidroz officer: Chief Accounting Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth director, officer: President and CEO 200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North officer: Chief Information Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton officer: Chief People Officer C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert officer: Chief Compliance Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato officer: Chief Strategy Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter director PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins director 500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard officer: Chief Operating Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout director 2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye director AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly officer: See Remarks 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816